Provided by Tiger Fintech (Singapore) Pte. Ltd.

SpringWorks Therapeutics, Inc.

46.78
-0.0800-0.17%
Post-market: 46.790.0100+0.02%19:19 EDT
Volume:8.07M
Turnover:377.71M
Market Cap:3.52B
PE:-13.71
High:46.90
Open:46.87
Low:46.74
Close:46.86
Loading ...

SpringWorks Therapeutics Announces Approval of Merger Agreement with Merck KGaA, Expects Completion in Second Half of 2025

Reuters
·
16 Jun

SpringWorks Therapeutics Inc. Announces Date for Special Stockholders Meeting

Reuters
·
28 May

Barclays Remains a Hold on Springworks Therapeutics (SWTX)

TIPRANKS
·
27 May

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

Reuters
·
23 May

Springworks Therapeutics Says Mirdametinib Recommended by EU Panel for Treating Plexiform Neurofibromas

MT Newswires Live
·
23 May

BRIEF-SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN

Reuters
·
23 May

SpringWorks Therapeutics Inc - European Commission Decision on Mirdametinib Expected Q3 2025

THOMSON REUTERS
·
23 May

SpringWorks Therapeutics Inc: Decision From European Commission Expected in Q3 2025

THOMSON REUTERS
·
23 May

SpringWorks Therapeutics Receives Positive Chmp Opinion for Mirdametinib for Treatment of Adult and Pediatric Patients With Nf1-Pn

THOMSON REUTERS
·
23 May

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib, European Commission Decision Expected in Q3 2025

Reuters
·
23 May

SpringWorks Therapeutics Inc. Announces Date for Special Stockholders Meeting

Reuters
·
16 May

Merck KGaA cautious on 2025 profit on currency effects, tariff uncertainty

Reuters
·
15 May

SpringWorks Therapeutics Inc. Held Annual Stockholders Meeting

Reuters
·
15 May

SpringWorks Therapeutics Price Target Maintained With a $47.00/Share by Guggenheim

Dow Jones
·
12 May

SpringWorks Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
10 May

Biotech Alert: Searches spiking for these stocks today

TipRanks
·
02 May

SpringWorks Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
30 Apr

HC Wainwright Downgrades Springworks Therapeutics to Neutral From Buy, Adjusts Price Target to $47 From $74

MT Newswires Live
·
30 Apr

SpringWorks Therapeutics, Inc. : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
30 Apr

SpringWorks Therapeutics Cut to Hold From Buy by TD Cowen

Dow Jones
·
29 Apr